Literature DB >> 3094056

Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.

D M Jackson, M Hashizume.   

Abstract

In mice pretreated with reserpine plus alpha-methyl-p-tyrosine, neither the D-2 selective agonist bromocriptine, nor the D-1 selective agonist SKF38393, produced any measurable increase in locomotion in mice. However, the combination of the two agonists produced a marked and dose-dependent increase in co-ordinated locomotor activity. In mice with their dopamine stores and dopamine synthesis intact, SKF38393 was inactive by itself, but significantly enhanced the stimulant effect produced by bromocriptine. The data suggest that bromocriptine requires concomitant stimulation of D-1 receptors for the full expression of its behavioural stimulant effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094056     DOI: 10.1007/bf00172888

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

3.  The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.

Authors:  J Y Lew; F Hata; T Ohashi; M Goldstein
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

4.  A pharmacological study of changes in central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration.

Authors:  R C Bailey; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

5.  Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.

Authors:  K Fuxe; B B Fredholm; L F Agnati; S O Ogren; B J Everitt; G Jonsson; J A Gustafsson
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

6.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

7.  Influence of chlorpromazine on spontaneous activity of mice under various parametric conditions.

Authors:  N Watzman; H Barry; W J Kinnard; J P Buckley
Journal:  Arch Int Pharmacodyn Ther       Date:  1967-02

8.  Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats.

Authors:  O F Jenkins; D M Jackson
Journal:  Neuropharmacology       Date:  1986-11       Impact factor: 5.250

9.  Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.

Authors:  O F Jenkins; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  The central effects of a novel dopamine agonist.

Authors:  P E Setler; H M Sarau; C L Zirkle; H L Saunders
Journal:  Eur J Pharmacol       Date:  1978-08-15       Impact factor: 4.432

View more
  21 in total

1.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

Authors:  P A Löschmann; L A Smith; K W Lange; P Jähnig; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats.

Authors:  M T Martin-Iverson; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

Review 6.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Relationship between D1 dopamine receptors, adenylate cyclase, and the electrophysiological responses of rat nucleus accumbens neurons.

Authors:  P A Johansen; X T Hu; F J White
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

9.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

10.  Role of dopamine receptors in the regulation of aggression in mice; relationship to genotype.

Authors:  E M Nikulina; N S Kapralova
Journal:  Neurosci Behav Physiol       Date:  1992 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.